Epizyme (NASDAQ:EPZM) Stock Rating Upgraded by BidaskClub

Epizyme (NASDAQ:EPZM) was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating in a report released on Wednesday, BidAskClub reports.

Several other equities research analysts also recently commented on the company. Zacks Investment Research downgraded Epizyme from a “buy” rating to a “hold” rating and set a $15.00 target price on the stock. in a report on Wednesday, August 14th. HC Wainwright set a $25.00 target price on Epizyme and gave the stock a “buy” rating in a report on Monday, June 24th. Wedbush reissued an “outperform” rating and issued a $21.00 target price on shares of Epizyme in a report on Wednesday, June 12th. Finally, Citigroup reissued a “buy” rating on shares of Epizyme in a report on Thursday, May 30th. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $18.11.

Epizyme stock opened at $13.28 on Wednesday. The company has a debt-to-equity ratio of 0.03, a current ratio of 10.56 and a quick ratio of 10.56. The business’s fifty day simple moving average is $12.98 and its two-hundred day simple moving average is $12.74. Epizyme has a 12 month low of $5.14 and a 12 month high of $16.59.

Epizyme (NASDAQ:EPZM) last released its earnings results on Friday, August 9th. The biopharmaceutical company reported ($0.53) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.51) by ($0.02). The business had revenue of $5.90 million during the quarter, compared to analyst estimates of $0.32 million. During the same quarter last year, the business earned ($0.42) earnings per share. The company’s quarterly revenue was down 50.8% on a year-over-year basis. Sell-side analysts predict that Epizyme will post -2.13 earnings per share for the current year.

In other news, Director David M. Mott sold 104,944 shares of the company’s stock in a transaction on Wednesday, June 26th. The stock was sold at an average price of $13.08, for a total transaction of $1,372,667.52. Following the transaction, the director now directly owns 13,979 shares of the company’s stock, valued at $182,845.32. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Robert B. Bazemore sold 2,074 shares of the company’s stock in a transaction on Thursday, June 13th. The shares were sold at an average price of $12.10, for a total value of $25,095.40. Following the transaction, the chief executive officer now directly owns 87,068 shares in the company, valued at $1,053,522.80. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 108,203 shares of company stock worth $1,412,101. Corporate insiders own 16.60% of the company’s stock.

Several large investors have recently made changes to their positions in EPZM. Victory Capital Management Inc. bought a new position in shares of Epizyme during the first quarter valued at $20,289,000. Vanguard Group Inc. lifted its holdings in shares of Epizyme by 29.9% during the second quarter. Vanguard Group Inc. now owns 7,078,470 shares of the biopharmaceutical company’s stock valued at $88,835,000 after purchasing an additional 1,630,171 shares in the last quarter. BlackRock Inc. lifted its holdings in Epizyme by 31.8% in the second quarter. BlackRock Inc. now owns 6,440,597 shares of the biopharmaceutical company’s stock valued at $80,831,000 after acquiring an additional 1,552,216 shares during the period. Norges Bank bought a new position in Epizyme in the fourth quarter valued at about $6,965,000. Finally, Redmile Group LLC lifted its holdings in Epizyme by 15.9% in the first quarter. Redmile Group LLC now owns 7,694,020 shares of the biopharmaceutical company’s stock valued at $95,329,000 after acquiring an additional 1,056,742 shares during the period. 83.65% of the stock is currently owned by hedge funds and other institutional investors.

About Epizyme

Epizyme, Inc, a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors.

Recommended Story: How do analysts define an oversold condition?

Analyst Recommendations for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit